

Michael R Verneris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5792545/publications.pdf>

Version: 2024-02-01

294
papers

16,315
citations

28272
55
h-index

17588
121
g-index

296
all docs

296
docs citations

296
times ranked

17143
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Advances, 2022, 6, 1961-1968.	5.2	47
2	Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Advances, 2022, 6, 600-610.	5.2	32
3	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. Journal of Clinical Oncology, 2022, 40, 945-955.	1.6	79
4	SAHA Enhances Differentiation of CD34+CD45+ Hematopoietic Stem and Progenitor Cells from Pluripotent Stem Cells Concomitant with an Increase in Hemogenic Endothelium. Stem Cells Translational Medicine, 2022, 11, 513-526.	3.3	5
5	Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Advances, 2022, 6, 4251-4255.	5.2	20
6	Abstract CT522: Feasibility and safety of a novel CD19 CAR T cell therapy in adults with R/R B-NHL. Cancer Research, 2022, 82, CT522-CT522.	0.9	0
7	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood, 2021, 137, 983-993.	1.4	20
8	Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2021, 62, 229-233.	1.3	0
9	Phase I Dose-Finding, Safety, and Tolerability Trial of Romiplostim to Improve Platelet Recovery After UCB Transplantation. Transplantation and Cellular Therapy, 2021, 27, 497.e1-497.e6.	1.2	8
10	Therapeutic manipulation of innate lymphoid cells. JCI Insight, 2021, 6, .	5.0	20
11	Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Frontiers in Immunology, 2021, 12, 607282.	4.8	19
12	An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT. Transplantation and Cellular Therapy, 2021, 27, 317-326.	1.2	11
13	Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. , 2021, 9, e002056.		52
14	Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. Blood Advances, 2021, 5, 4064-4072.	5.2	17
15	Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. Transplantation and Cellular Therapy, 2021, 27, 926.e1-926.e10.	1.2	2
16	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 642-649.	1.2	65
17	Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood, 2021, 138, 2138-2142.	1.4	5
18	Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia. Blood Advances, 2021, 5, 5387-5395.	5.2	7

#	ARTICLE	IF	CITATIONS
19	Donor Socioeconomic Status As a Predictor of Altered Immune Function and Treatment Response Following Hematopoietic Cell Transplantation for Hematologic Malignancy. <i>Blood</i> , 2021, 138, 843-843.	1.4	1
20	KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 256-256.	1.4	10
21	A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant. <i>Blood</i> , 2021, 138, 2887-2887.	1.4	0
22	Inhibiting Efferocytosis in Acute Myeloid Leukemia Decreases Checkpoint Blockade through Decreased CCL5/STAT6 Signaling and Increases Activation through NF-Kb. <i>Blood</i> , 2021, 138, 1174-1174.	1.4	0
23	Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 606-611.	2.0	3
24	Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2020, 80, 458-470.	0.9	46
25	What Is the Optimal Post-Transplant Cardiac Screening for Transplant Recipients with a Non-Malignant Disease?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S351.	2.0	0
26	Comparison of Haploidentical Related Donor with Post-Transplant Cyclophosphamide (PTCy) and Umbilical Cord Blood (UCB) Transplantation after Myeloablative Conditioning for Hematological Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S291.	2.0	2
27	Autoimmune Cytopenias Following Allogeneic Hematopoietic Stem Cell Transplant in Pediatric Patients: A Case-Control Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S128-S129.	2.0	0
28	Autoimmune cytopenias following allogeneic hematopoietic stem cell transplant in pediatric patients: Response to therapy and late effects. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28591.	1.5	13
29	Human innate lymphoid cell precursors express CD48 that modulates ILC differentiation through 2B4 signaling. <i>Science Immunology</i> , 2020, 5, .	11.9	10
30	Therapeutic effect of TRC105 and decitabine combination in AML xenografts. <i>Heliyon</i> , 2020, 6, e05242.	3.2	2
31	Glycemic variability is associated with poor outcomes in pediatric hematopoietic stem cell transplant patients. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28626.	1.5	2
32	Decrease in T-Lymphocyte Mitochondrial DNA Copy Number Is Associated with Acute Graft Versus Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S176-S177.	2.0	0
33	Prolactin Acts on Myeloid Progenitors to Modulate SMAD7 Expression and Enhance Hematopoietic Stem Cell Differentiation into the NK Cell Lineage. <i>Scientific Reports</i> , 2020, 10, 6335.	3.3	8
34	Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. <i>Blood Advances</i> , 2020, 4, 1350-1356.	5.2	19
35	Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function. <i>JCI Insight</i> , 2020, 5, .	5.0	35
36	Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC). <i>Blood</i> , 2020, 136, 14-15.	1.4	25

#	ARTICLE	IF	CITATIONS
37	Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release. <i>Blood</i> , 2020, 136, 42-44.	1.4	8
38	Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 581107.	2.8	14
39	Outcomes of Pediatric Patients with JMML Following Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching. <i>Blood</i> , 2020, 136, 42-43.	1.4	0
40	Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 12-18.	2.0	4
41	The Human TET2 Gene Contains Three Distinct Promoter Regions With Differing Tissue and Developmental Specificities. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 99.	3.7	8
42	Molecular Correlates of Socioeconomic Status and Clinical Outcomes Following Hematopoietic Cell Transplantation for Leukemia. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz073.	2.9	18
43	Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2357-2365.	2.0	9
44	A novel human <i>IL2RB</i> mutation results in T and NK cell-driven immune dysregulation. <i>Journal of Experimental Medicine</i> , 2019, 216, 1255-1267.	8.5	64
45	Mixed vs full donor engraftment early after hematopoietic cell transplant: Impact on incidence and control of cytomegalovirus infection. <i>Transplant Infectious Disease</i> , 2019, 21, e13070.	1.7	4
46	Transient Expression of GATA3 in Hematopoietic Stem Cells Facilitates Helper Innate Lymphoid Cell Differentiation. <i>Frontiers in Immunology</i> , 2019, 10, 510.	4.8	10
47	Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors. <i>Bone Marrow Transplantation</i> , 2019, 54, 1605-1613.	2.4	7
48	Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients. <i>Blood Advances</i> , 2019, 3, 350-359.	5.2	12
49	Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 1926-1929.	5.2	53
50	The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1118-1128.	5.2	42
51	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019, 3, 3393-3405.	5.2	81
52	Analysis of Single Nucleotide Polymorphisms in the Gamma Block of the Major Histocompatibility Complex in Association with Clinical Outcomes of Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 664-672.	2.0	3
53	Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 883-890.	2.0	14
54	Donor-specific anti-HLA antibodies in unrelated hematopoietic cell transplantation for non-malignant disorders. <i>Bone Marrow Transplantation</i> , 2019, 54, 494-496.	2.4	5

#	ARTICLE	IF	CITATIONS
55	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 301-306.	2.0	27
56	The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation – a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR. <i>Bone Marrow Transplantation</i> , 2019, 54, 849-857.	2.4	2
57	Romiplostim Improves Platelet Recovery after UCB Transplant. <i>Blood</i> , 2019, 134, 1979-1979.	1.4	1
58	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. <i>Blood</i> , 2018, 131, 2515-2527.	1.4	307
59	Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1049-1056.	2.0	98
60	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 932-937.	2.4	1
61	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 439-448.	27.0	3,680
62	Evaluation of a Machine Learning-Based Prognostic Model for Unrelated Hematopoietic Cell Transplantation Donor Selection. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1299-1306.	2.0	16
63	No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 383-391.	2.4	13
64	Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 827-831.	2.0	1
65	Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2018, 24, 1504-1506.	30.7	393
66	Analysis of Single Nucleotide Polymorphisms (SNP) Donor/Recipient Mismatches in the Gamma Block of the Major Histocompatibility Complex (MHC) and Their Association with Hematopoietic Cell Transplantation (HCT) Outcomes: A CIBMTR Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S417-S418.	2.0	1
67	Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. <i>Blood Advances</i> , 2018, 2, 909-922.	5.2	76
68	In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance. <i>Blood Advances</i> , 2018, 2, 1773-1783.	5.2	23
69	Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1651-1656.	2.0	18
70	Malglycemia is Associated with Increased Mortality in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S61-S62.	2.0	0
71	Transplantation of CCR5 Δ 32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV Infection. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy090.	0.9	15
72	Prediction of absolute risk of acute graft-versus-host disease following hematopoietic cell transplantation. <i>PLoS ONE</i> , 2018, 13, e0190610.	2.5	20

#	ARTICLE	IF	CITATIONS
73	Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 618-622.	2.0	13
74	Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors. <i>Oncotarget</i> , 2018, 9, 11938-11947.	1.8	19
75	The Role of HLA-E Polymorphism in Acute Leukemia Patients Receiving a 10/10 HLA Matched Unrelated HSCT. <i>Blood</i> , 2018, 132, 310-310.	1.4	0
76	Outcomes of Pediatric Patients with Acute Leukemia Following Adult Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching. <i>Blood</i> , 2018, 132, 4647-4647.	1.4	0
77	Impact of Delayed Infusion Time in Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 836-839.	2.0	0
78	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 376, 536-547.	27.0	586
79	Dose Escalation of Total Marrow Irradiation in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1110-1116.	2.0	40
80	Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells. <i>Blood</i> , 2017, 129, 3428-3439.	1.4	56
81	Mixed Versus Full Donor Engraftment Early after Allogeneic Stem Cell Transplant: The Impact on Incidence and Control of Cytomegalovirus Reactivation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S189-S190.	2.0	1
82	Monitoring of MRD before and after Allogeneic Hematopoietic Cell Transplantation (HCT) of Childhood ALL by FC and RQ-PCR: A Retrospective Assessment on Behalf of the Pdpw of the Ebmt, the Cog, the Pbmct, the I-Bfm and the Westhafen-Intercontinental-Group. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S22-S23.	2.0	0
83	Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models. <i>Blood</i> , 2017, 129, 2526-2536.	1.4	23
84	Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1029-1037.	2.0	10
85	MHC Class I Chain-Related Gene A (MICCA) Donor-Recipient Mismatches and MICCA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 436-444.	2.0	22
86	A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. <i>Blood</i> , 2017, 129, 740-758.	1.4	35
87	Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S263-S264.	0.4	41
88	Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1925-1931.	2.0	5
89	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-“Matched Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 126-133.	2.0	10
90	Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 153-160.	2.0	12

#	ARTICLE	IF	CITATIONS
91	Whole-Body Distribution of Leukemia and Functional Total Marrow Irradiation Based on FLT-PET and Dual-Energy CT. <i>Molecular Imaging</i> , 2017, 16, 153601211773220.	1.4	12
92	Analysis of 10,462 8/8 HLA- Matched Unrelated Donor Transplants Could Not Identify a Donor Selection Score, As Younger Age Is the Only Significant Donor Characteristic Associated with Survival. <i>Blood</i> , 2017, 130, 848-848.	1.4	0
93	Fewer circulating natural killer cells 28 days after double cord blood transplantation predicts inferior survival and IL-15 response. <i>Blood Advances</i> , 2016, 1, 208-218.	5.2	9
94	Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD. <i>Haematologica</i> , 2016, 101, e348-e351.	3.5	5
95	Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1159-1166.	2.0	24
96	Umbilical cord bloodâ€‘derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. <i>Blood</i> , 2016, 127, 1044-1051.	1.4	333
97	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71
98	Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2016, 101, 1267-1274.	3.5	22
99	Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2016, 76, 5696-5706.	0.9	146
100	Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitorâ€‘Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2025-2030.	2.0	27
101	Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 825-833.	2.0	11
102	Validation Study Failed to Confirm an Association between Genetic Variants in the Base Excision Repair Pathway and Transplant-Related Mortality and Relapse after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1531-1532.	2.0	6
103	Angiogenic Factors, Inflammation, and Outcomes in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Biomarker Analysis of Gvhd Prophylaxis in Blood and Marrow Transplant Clinical Trials Network Protocol (BMT CTN) 0402. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S70-S71.	2.0	2
104	Dendritic Cells Recovery after Umbilical Cord Blood Transplant Is Superior to Related Donor Transplant and Predicts Better Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S156.	2.0	0
105	Sirolimus/Mycophenolate Mofetil (MMF): Effective Calcineurin Inhibitor-Free GVHD Prophylaxis for Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S305.	2.0	1
106	Marrow damage and hematopoietic recovery following allogeneic bone marrow transplantation for acute leukemias: Effect of radiation dose and conditioning regimen. <i>Radiotherapy and Oncology</i> , 2016, 118, 65-71.	0.6	24
107	IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, <i>In Vivo</i> Expansion, and Enhanced Function. <i>Clinical Cancer Research</i> , 2016, 22, 3440-3450.	7.0	291
108	Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 487-492.	2.0	44

#	ARTICLE	IF	CITATIONS
109	Is It Better to Be Rich or Relaxed? Sociobiology Meets Bone Marrow Transplant. Clinical Cancer Research, 2016, 22, 6-8.	7.0	3
110	Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function. Blood, 2016, 128, 1225-1225.	1.4	3
111	Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 2016, 128, 221-221.	1.4	62
112	Monocyte Subpopulation Recovery and Outcomes Following Hematopoietic Cell Transplantation. Blood, 2016, 128, 2232-2232.	1.4	3
113	Immune Reconstitution after Umbilical Cord Blood Versus Peripheral Blood Progenitor Cell Transplantation in Adults Following Myeloablative Conditioning. Blood, 2016, 128, 2246-2246.	1.4	4
114	Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis. Blood, 2016, 128, 2801-2801.	1.4	58
115	CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics. Blood, 2016, 128, 4291-4291.	1.4	8
116	Role of Recipient CD8+ T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells. Blood, 2016, 128, 503-503.	1.4	2
117	Donor Telomere Length and Outcomes after Allogeneic Unrelated Hematopoietic Cell Transplant in Patients with Acute Leukemia. Blood, 2016, 128, 520-520.	1.4	1
118	High Peripheral Blood Stem Cell (PBSC) CD34+ Cell Dose Increases the Risk of Chronic Gvhd after Human Leukocyte Antigen (HLA) Matched Sibling Transplantation. Blood, 2016, 128, 5877-5877.	1.4	2
119	Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 69-69.	1.4	2
120	Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMT, the I-BFM and the Westhafen-Intercontinental-Group. Blood, 2016, 128, 985-985.	1.4	2
121	Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity. Oncotarget, 2016, 7, 76047-76061.	1.8	17
122	Fewer Circulating Natural Killer Cells 28 Days after Double Cord Blood Transplantation (dUCBT) Predicts Inferior Survival and IL-15 Response. Blood, 2016, 128, 2231-2231.	1.4	0
123	Immune Reconstitution (IR) after Allogeneic Hematopoietic Cell Transplantation (alloHCT): Comparing Results in Recipients of Unrelated Umbilical Cord Blood (UCB) to Those with an HLA-Matched Sibling Donor Peripheral Blood (MSD PB). Blood, 2016, 128, 4590-4590.	1.4	0
124	Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402. Blood, 2016, 128, 63-63.	1.4	0
125	Endoglin (CD105) in AML: A Potential Novel Target for Therapeutic Intervention. Blood, 2016, 128, 5211-5211.	1.4	0
126	Haploidentical Natural Killer Cell Infusion Induces Remission in Non-Hodgkin Lymphoma and Overcomes Resistance to Rituximab. Blood, 2016, 128, 3030-3030.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Germline Mutations in Patients Receiving Unrelated Donor Hematopoietic Cell Transplant for Severe Aplastic Anemia. <i>Blood</i> , 2016, 128, 68-68.	1.4	0
128	Pilot Study of Prognostic Impact of Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Plasma Levels of CXC-Chemokines (CXCL-4 and CXCL-7) in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 4678-4678.	1.4	0
129	Adaptive NK Cell Expansion Is Associated with Reduced Relapse of Lymphoid Malignancies after Autologous Hematopoietic Cell Transplant. <i>Blood</i> , 2016, 128, 515-515.	1.4	0
130	Preservation of Ovarian Function after Hematopoietic Cell Transplantation (HCT): More Possible Than We Thought?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S178.	2.0	0
131	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2154-2159.	2.0	25
132	Pre-Transplant Serum Biomarkers Predict Early Relapse in Classical Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S144-S145.	2.0	0
133	Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-22-dependent proliferation. <i>European Journal of Immunology</i> , 2015, 45, 2335-2342.	2.9	38
134	Second allogeneic hematopoietic cell transplantation for graft failure: Poor outcomes for neutropenic graft failure. <i>American Journal of Hematology</i> , 2015, 90, 892-896.	4.1	27
135	Natural Killer Cell Adoptive Transfer Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 486-491.	2.0	99
136	Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1653-1662.	2.0	50
137	Prevention of Acute GVHD by Ex Vivo Expanded Umbilical Cord Blood Derived Regulatory T Cells (Treg). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S55-S56.	2.0	0
138	Circulating Angiogenic Factors Associated with Response and Survival in Patients with Acute Graft-versus-Host Disease: Results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1029-1036.	2.0	53
139	Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1589-1596.	2.0	37
140	Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 1267-1272.	7.0	60
141	Second Allogeneic Hematopoietic Cell Transplantation for Graft Failure: Poorer Outcomes for Neutropenic Graft Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S166-S167.	2.0	2
142	HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1783-1789.	2.0	83
143	The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. <i>Current Topics in Microbiology and Immunology</i> , 2015, 395, 225-243.	1.1	28
144	An Exploratory Analysis of Mitochondrial Haplotypes and Allogeneic Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 81-88.	2.0	9

#	ARTICLE	IF	CITATIONS
145	Multi-institutional Feasibility Study of a Fast Patient Localization Method in Total Marrow Irradiation With Helical Tomotherapy: A Global Health Initiative by the International Consortium of Total Marrow Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 30-38.	0.8	14
146	Impact of Long-Term Cryopreservation on Single Umbilical Cord Blood Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 50-54.	2.0	29
147	'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15R α -Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy. <i>Blood</i> , 2015, 126, 1957-1957.	1.4	7
148	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2015, 126, 2022-2022.	1.4	1
149	Trispecific Killer Engagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion. <i>Blood</i> , 2015, 126, 232-232.	1.4	8
150	Similar Survival after Umbilical Cord Blood (UCB) and HLA-Matched Adult Donor Transplantation By Disease Risk Index (DRI) Assignment. <i>Blood</i> , 2015, 126, 4375-4375.	1.4	3
151	A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFN γ Production and Competition Between Donor NK and Recipient T Cells. <i>Blood</i> , 2015, 126, 566-566.	1.4	2
152	Investigating Effect of Genetic Admixture and Donor/Recipient Genetic Disparity on Transplant Outcomes. <i>Blood</i> , 2015, 126, 3229-3229.	1.4	0
153	Defining Successful Immune Reconstitution (IR) after Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2015, 126, 1934-1934.	1.4	0
154	Notch Signaling at Later Stages of NK Cell Development Enhances KIR Expression and Functional Maturation. <i>Journal of Immunology</i> , 2014, 193, 3344-3354.	0.8	51
155	Cytotoxic T-Lymphocyte Antigen-4 Single Nucleotide Polymorphisms Are Not Associated with Outcomes after Unrelated Donor Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 900-903.	2.0	10
156	The biology of <sc>NK</sc> cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (<sc>HCT</sc>). <i>Immunological Reviews</i> , 2014, 258, 45-63.	6.0	83
157	Clinical utility of natural killer cells in cancer therapy and transplantation. <i>Seminars in Immunology</i> , 2014, 26, 161-172.	5.6	154
158	CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. <i>Blood</i> , 2014, 123, 3016-3026.	1.4	220
159	One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers. <i>New England Journal of Medicine</i> , 2014, 371, 1685-1694.	27.0	246
160	The Effects of 1,25-Dihydroxyvitamin D3 on In Vitro Human NK Cell Development from Hematopoietic Stem Cells. <i>Journal of Immunology</i> , 2014, 193, 3456-3462.	0.8	45
161	A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2014, 89, 889-895.	4.1	82
162	Prevention of Graft-versus-Host Disease by Adoptive T Regulatory Therapy Is Associated with Active Repression of Peripheral Blood Toll-Like Receptor 5 mRNA Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 173-182.	2.0	28

#	ARTICLE	IF	CITATIONS
163	Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine Administration: Implications for Clinical Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1252-1257.	2.0	71
164	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. <i>Blood</i> , 2014, 123, 3855-3863.	1.4	357
165	Circulating Angiogenic Factors As Biomarkers of Acute Gvhd Onset and Response to Therapy: Repair and Regeneration Versus Endothelial Damage and Inflammation. <i>Blood</i> , 2014, 124, 2489-2489.	1.4	1
166	Relationship of Epidermal Growth Factor to Cyclosporine-Associated Magnesium Wasting and Clinical Outcomes Post-Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 3914-3914.	1.4	2
167	CMV Reactivation is Associated with Reduced Relapse Risk, Better Disease-Free Survival and Expansion of Adaptive NK Cells after Reduced Intensity Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 668-668.	1.4	2
168	Stem Cell Source Dependent Differences in Reconstituting Peripheral T Follicular Helper Cells Following Hematopoietic Cell Transplantation, Their Association with Chronic Gvhd and Role in Response to Influenza Vaccination. <i>Blood</i> , 2014, 124, 3919-3919.	1.4	0
169	Clonal Expansion of Adaptive NK Cells and NKG2C+CD57+ KIR-Expressing T Cells from Sibling, but Not Umbilical Cord Blood, Grafts Is Induced By Recipient Latent CMV and Is Associated with Protection Against CMV Reactivation. <i>Blood</i> , 2014, 124, 181-181.	1.4	0
170	The Prognostic Value of YKL-40 in Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 1176-1176.	1.4	0
171	Remission Induction in a Phase 1 Study of a Bispecific Single Chain Immunotoxin Targeting CD22 and CD19 (DT2219) for Refractory B-Cell Malignancies. <i>Blood</i> , 2014, 124, 3098-3098.	1.4	0
172	Acute Graft Versus Host Disease after Donor Lymphocyte Infusion: A Single Center Analysis. <i>Blood</i> , 2014, 124, 5807-5807.	1.4	0
173	Clinical Relevance of HLA Supertype Matching after Myeloablative Conditioning 7/8 Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Study. <i>Blood</i> , 2014, 124, 2572-2572.	1.4	0
174	Mitochondrial Haplotype As an Independent Predictor of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2014, 124, 683-683.	1.4	0
175	Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. <i>Pediatric Blood and Cancer</i> , 2013, 60, 705-710.	1.5	31
176	Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 138-142.	2.0	36
177	Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 274-282.	1.0	81
178	Peripheral Dose Heterogeneity Due to the Thread Effect in Total Marrow Irradiation With Helical Tomotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 832-839.	0.8	10
179	Lineage relationships of human interleukin-22-producing CD56+ ROR γ t ⁺ innate lymphoid cells and conventional natural killer cells. <i>Blood</i> , 2013, 121, 2234-2243.	1.4	51
180	A Randomized Trial of One versus Two Doses of Influenza Vaccine after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 109-116.	2.0	57

#	ARTICLE	IF	CITATIONS
181	Allogeneic Hematopoietic Cell Transplantation in First Remission Abrogates Poor Outcomes Associated with High-Risk Pediatric Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1021-1025.	2.0	27
182	How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. <i>American Journal of Hematology</i> , 2013, 88, 826-827.	4.1	2
183	Targeting Natural Killer Cells to Acute Myeloid Leukemia<i>In Vitro</i>with a CD16 Å— 33 Bispecific Killer Cell Engager and ADAM17 Inhibition. <i>Clinical Cancer Research</i> , 2013, 19, 3844-3855.	7.0	208
184	Pericardial effusion after pediatric hematopoietic cell transplant. <i>Pediatric Transplantation</i> , 2013, 17, 294-299.	1.0	28
185	Influence Of Killer Immunoglobulin-Like Receptor (KIR) and HLA Genotypes On Outcomes After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation For Patients With AML and MDS: A Report From The Center For International Blood and Marrow Transplant Research Immunobiology Working Committee. <i>Blood</i> , 2013, 122, 159-159.	1.4	2
186	Death Receptor 3 (DR3) Is Expressed By Innate Lymphoid Cells (ILC) and Ligation By Tumor Like Antigen-1 (TL1A) Leads To Costimulation and Significant ILC Expansion. <i>Blood</i> , 2013, 122, 782-782.	1.4	2
187	CD161 Expression Identifies a Distinct Subset Of Drug-Effluxing Viral-Specific Memory CD4+ T Cells That Preferentially Survive Cytotoxic Chemotherapy. <i>Blood</i> , 2013, 122, 2024-2024.	1.4	0
188	Higher CSA Levels After Umbilical Cord Blood Transplant For Acute Leukemia Result In Improved Survival. <i>Blood</i> , 2013, 122, 2097-2097.	1.4	0
189	Early NK Cell Proliferation After Umbilical Cord Blood Transplantation Is Associated With Superior Disease-Free Survival Due To Reduced Leukemia Relapse. <i>Blood</i> , 2013, 122, 4610-4610.	1.4	0
190	Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2674-2684.	4.1	202
191	Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. <i>Blood</i> , 2012, 119, 2665-2674.	1.4	581
192	Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen. <i>Journal of Immunology</i> , 2012, 189, 5082-5088.	0.8	331
193	Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. <i>Blood</i> , 2012, 119, 3064-3072.	1.4	318
194	Impact of Bone Marrow Hematogones on Umbilical Cord Blood Transplantation Outcomes in Patients with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 930-936.	2.0	26
195	Natural Killer Cell Differentiation from Hematopoietic Stem Cells: A Comparative Analysis of Heparin- and Stromal Cell-Supported Methods. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 536-545.	2.0	29
196	Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 480-486.	2.0	43
197	The Epic Race to Immune Reconstitution. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 493-494.	2.0	1
198	Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 963-968.	2.0	48

#	ARTICLE	IF	CITATIONS
199	Treatment of relapsed acute lymphoblastic leukemia: Approaches used by pediatric oncologists and bone marrow transplant physicians. <i>Pediatric Blood and Cancer</i> , 2012, 58, 840-845.	1.5	4
200	Optimal Xenogeneic Adoptive Transfer of Human NK Cells: Fresh NK Cells and IL-15 Administration Are Superior to Frozen NK Cells and IL-2. <i>Blood</i> , 2012, 120, 346-346.	1.4	1
201	A Phase II Trial of Decitabine and Vorinostat in Combination with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 4307-4307.	1.4	3
202	Recombinant Human IL-15 Promotes in Vivo Expansion of Adoptively Transferred NK Cells in a First-in-Human Phase I Dose Escalation Study in Patients with AML. <i>Blood</i> , 2012, 120, 894-894.	1.4	9
203	Bi-Specific Killer Cell Engagers (BiKEs) Signaling Through CD16 and Targeting CD33 (CD16 Å— CD33), Triggers Natural Killer (NK) Cell Cytotoxic and Cytokine Production Against Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012, 120, 256-256.	1.4	1
204	Increased Relapse Associated with Mixed Donor-Donor Chimerism Following Double Umbilical Cord Blood Transplantation (dUCBT). <i>Blood</i> , 2012, 120, 358-358.	1.4	0
205	A Randomized Trial of One Vs. Two Doses of Influenza Vaccine Following Allogeneic Transplantation. <i>Blood</i> , 2012, 120, 1896-1896.	1.4	0
206	The Effect of Transplant Center Characteristics On Survival After Pediatric Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 762-762.	1.4	1
207	Allele Level HLA Matching On Outcomes After Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies: Stronger Graft Vs. Leukemia with HLA Mismatch. <i>Blood</i> , 2012, 120, 1976-1976.	1.4	0
208	Alternative Donor Hematopoietic Cell Transplantation for Patients with Fanconi Anemia.. <i>Blood</i> , 2012, 120, 3081-3081.	1.4	1
209	Human IL-22 Producing CD56+ RORÎ³t+ Innate Lymphoid Cells and Conventional NK Cells Have Distinctive Developmental Trajectories and Are Separate Cell Lineages. <i>Blood</i> , 2012, 120, 1219-1219.	1.4	0
210	Early Lymphocyte Recovery and Outcomes after Umbilical Cord Blood Transplantation (UCBT) for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 831-840.	2.0	56
211	Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1025-1032.	2.0	32
212	Natural killerâ€™ cell differentiation by myeloid progenitors. <i>Blood</i> , 2011, 117, 3548-3558.	1.4	107
213	Development of IL-22â€™producing NK lineage cells from umbilical cord blood hematopoietic stem cells in the absence of secondary lymphoid tissue. <i>Blood</i> , 2011, 117, 4052-4055.	1.4	58
214	Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. <i>Blood</i> , 2011, 117, 5261-5263.	1.4	15
215	NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. <i>Blood</i> , 2011, 118, 2784-2792.	1.4	117
216	Peritransplant palifermin use and lymphocyte recovery after Tâ€™cell replete, matched related allogeneic hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2011, 86, 879-882.	4.1	17

#	ARTICLE	IF	CITATIONS
217	ADAM17, a Novel Metalloproteinase, Mediates CD16 and CD62L Shedding in Human NK Cells and Modulates IFN γ Responses. Blood, 2011, 118, 2184-2184.	1.4	7
218	Haploidentical Natural Killer (NK) Cells Expanding In Vivo After Adoptive Transfer Exhibit Hyperfunction That Partially Overcomes Self Tolerance and Leads to Clearance of Refractory Leukemia. Blood, 2011, 118, 355-355.	1.4	5
219	Natural Killer (NK) Cells Respond to CMV Reactivation After Allogeneic Transplantation with An Increase in NKG2C+CD57+ Self-KIR+ NK Cells with Potent IFN γ Production. Blood, 2011, 118, 356-356.	1.4	3
220	IL-2 Stimulated Treg Inhibit In Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo,. Blood, 2011, 118, 3611-3611.	1.4	0
221	Unrelated Cord Blood Transplantation (UCBT) in Adult and Pediatric Acute Lymphoblastic Leukemia: Impact of Minimal Residual Disease on Relapse and Survival,. Blood, 2011, 118, 4114-4114.	1.4	0
222	The Impact of Bone Marrow Hematogones on Umbilical Cord Blood Transplant Outcomes in Acute Myeloid Leukemia Patients,. Blood, 2011, 118, 4148-4148.	1.4	0
223	Early Hematopoietic Stem Cell Transplant Is Associated with Improved Outcomes in Children with MDS,. Blood, 2011, 118, 4126-4126.	1.4	0
224	Elevated Absolute Lymphocyte Counts Following Acute Graft Vs. Host Disease Treatment Is Associated with Therapeutic Responses and Lower Non-Relapse Mortality Following Umbilical Cord Blood Transplant,. Blood, 2011, 118, 4085-4085.	1.4	0
225	UCB and atmospheric noise. Blood, 2010, 115, 754-755.	1.4	5
226	Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood, 2010, 116, 4693-4699.	1.4	456
227	Novel Approaches to Prevent Leukemia Relapse Following Allogeneic Hematopoietic Cell Transplantation. Current Hematologic Malignancy Reports, 2010, 5, 157-162.	2.3	6
228	Costs of pediatric allogeneic hematopoietic cell transplantation. Pediatric Blood and Cancer, 2010, 54, 138-143.	1.5	46
229	Killing the Killer: Natural Killer Cells to Treat Ewing's Sarcoma. Clinical Cancer Research, 2010, 16, 3819-3821.	7.0	23
230	Impact of Cytomegalovirus (CMV) Reactivation after Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 215-222.	2.0	84
231	Natural Killer Cell Killing of Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Blasts by Killer Cell Immunoglobulin-Like Receptor α 1-3-Positive Natural Killer Cells after NKG2A and LIR-1 Blockade. Biology of Blood and Marrow Transplantation, 2010, 16, 612-621.	2.0	87
232	Reduced-Intensity Conditioning Regimens for Allogeneic Transplantation in Children with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 1237-1244.	2.0	42
233	The TREC to less CMV after UCBT. Blood, 2010, 115, 4009-4010.	1.4	0
234	Kinetics of Chimerism and Unit Predominance After Double Umbilical Cord Blood Transplantation. Blood, 2010, 116, 225-225.	1.4	6

#	ARTICLE	IF	CITATIONS
235	Tim-3, a Novel Immune Receptor, Is Constitutively Expressed on Human Natural Killer Cells and Functions as An Activating Coreceptor. <i>Blood</i> , 2010, 116, 106-106.	1.4	0
236	Impact of Graft Source on Immune Recovery: Comparisons Between Unrelated Umbilical Cord Blood (UCB), HLA Matched Sibling (Sib) Donor and Autologous (Auto) Hematopoietic Stem Cells.. <i>Blood</i> , 2010, 116, 3731-3731.	1.4	0
237	Allogeneic Hematopoietic Stem Cell Transplantation Overcomes the Adverse Prognostic Impact of CD20 Expression In Both Adult and Pediatric Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2010, 116, 1681-1681.	1.4	0
238	In Vitro Generation of NK22 Cells From Hematopoietic Stem Cells. <i>Blood</i> , 2010, 116, 108-108.	1.4	0
239	Alternative Donor Hematopoietic Cell Transplantation In 94 Patients with Fanconi Anemia at the University of Minnesota. <i>Blood</i> , 2010, 116, 3526-3526.	1.4	3
240	NK Education: Disassociation Between Recovery of Cytotoxicity and Cytokine Production In NK Cells After Allogeneic Transplantation.. <i>Blood</i> , 2010, 116, 1462-1462.	1.4	0
241	Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome. <i>Journal of Clinical Oncology</i> , 2009, 27, 3634-3641.	1.6	92
242	Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosomeâ€positive acute lymphoblastic leukemia (ALL). <i>Pediatric Blood and Cancer</i> , 2009, 53, 1289-1294.	1.5	32
243	The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. <i>British Journal of Haematology</i> , 2009, 147, 185-191.	2.5	85
244	O-Glycoside Biomarker of Apolipoprotein C3: Responsiveness to Obesity, Bariatric Surgery, and Therapy with Metformin, to Chronic or Severe Liver Disease and to Mortality in Severe Sepsis and Graft vs Host Disease. <i>Journal of Proteome Research</i> , 2009, 8, 603-612.	3.7	36
245	Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated Marrow and Umbilical Cord Blood versus Marrow from HLA Matched Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1086-1093.	2.0	60
246	Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. <i>Blood</i> , 2009, 113, 2410-2415.	1.4	191
247	Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. <i>Blood</i> , 2009, 113, 6094-6101.	1.4	231
248	Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. <i>Blood</i> , 2009, 113, 2902-2905.	1.4	106
249	Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. <i>Blood</i> , 2009, 113, 5628-5634.	1.4	147
250	Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. <i>Blood</i> , 2009, 114, 4293-4299.	1.4	276
251	Reduced Relapse and Similar Progression-Free Survival After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem Cell (HSC) Donors.. <i>Blood</i> , 2009, 114, 662-662.	1.4	5
252	Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) for Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2009, 114, 3377-3377.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Use of natural killer cells as immunotherapy for leukaemia. Best Practice and Research in Clinical Haematology, 2008, 21, 467-483.	1.7	35
254	Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System. Biology of Blood and Marrow Transplantation, 2008, 14, 685-692.	2.0	24
255	Umbilical Cord Blood T Cells Express Multiple Natural Cytotoxicity Receptors after IL-15 Stimulation, but Only NKp30 Is Functional. Journal of Immunology, 2008, 181, 4507-4515.	0.8	37
256	Blocking Inhibitory KIR Is Insufficient for Optimal Killing of AML and ALL Targets: Additional Requirements for NKG2A and LIR-1 Blockade. Blood, 2008, 112, 2906-2906.	1.4	10
257	Successful Haploidentical Hematopoietic Cell Engraftment Using a Non-Myeloablative Preparative Regimen Including Natural Killer (NK) Cells. Blood, 2008, 112, 827-827.	1.4	15
258	Prolonged Survival in Adults with Acute Lymphoblastic Leukemia (ALL) Following Reduced Intensity Conditioning and Allogeneic Transplantation. Blood, 2008, 112, 4415-4415.	1.4	0
259	Negative Effect of KIR Alloreactivity in Recipients of Umbilical Cord Blood Transplantation Depends on Transplantation Conditioning Intensity. Blood, 2008, 112, 152-152.	1.4	0
260	Identification of a Myeloid Pathway of NK Cell Development and a Myeloid- NK Cell Precursor. Blood, 2008, 112, 103-103.	1.4	4
261	Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood, 2007, 109, 5058-5061.	1.4	270
262	28: Reduced Risk of Leukemia Relapse after Double UCB Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 1402-1403.	2.0	0
263	iTRAQ Is a Useful Method To Screen for Membrane-Bound Proteins Differentially Expressed in Human Natural Killer Cell Types. Journal of Proteome Research, 2007, 6, 644-653.	3.7	67
264	Recent Developments in Cell-based Immune Therapy for Neuroblastoma. Journal of NeuroImmune Pharmacology, 2007, 2, 134-139.	4.1	8
265	Umbilical Cord Blood T Cells Express the Natural Cytotoxicity Receptors, NKp30, NKp44 and NKp46 after IL-15 Stimulation, but Only NKp30 Is Functional.. Blood, 2007, 110, 61-61.	1.4	0
266	Killer Immunoglobulin Receptor (KIR) Negative NK Cells Exhibit Potent Alloreactivity Against Primary Leukemia Targets When Interrupting MHC Class I Interactions through NKG2A Blockade.. Blood, 2007, 110, 2862-2862.	1.4	0
267	Stromal Cells Support a Myeloid Pathway of Human NK Cell Differentiation.. Blood, 2007, 110, 1336-1336.	1.4	0
268	Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood, 2006, 108, 3824-3833.	1.4	138
269	Studying multiple protein profiles over time to assess biomarker validity. Expert Review of Proteomics, 2006, 3, 455-464.	3.0	16
270	KIR Ligand Absence in Recipients of Unrelated Donor (URD) Allogeneic Hematopoietic Cell Transplantation (HCT) Is Associated with Less Relapse and Increased Graft Versus Host Disease (GVHD).. Blood, 2006, 108, 171-171.	1.4	4

#	ARTICLE	IF	CITATIONS
271	A Novel Triple Umbilical Cord Blood Transplant (UCBT) Strategy To Promote NK Cell Immunotherapy (Unit 1) with a Fully Ablative Preparative Regimen Followed by a Double UCBT in Patients with Refractory AML.. Blood, 2006, 108, 3111-3111.	1.4	3
272	Promising Progression Free and Overall Survival Using a Novel (CY/FLU/TBI) Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Sibling Stem Cell Transplantation (SCT).. Blood, 2006, 108, 2999-2999.	1.4	0
273	Hematopoietic Cell Transplantation as Therapy for Pediatric Patients with Relapsed Acute Lymphoblastic Leukemia with and without CNS Involvement.. Blood, 2006, 108, 3110-3110.	1.4	0
274	Outcome of CNS and pulmonary enteroviral infections after hematopoietic cell transplantation. Pediatric Blood and Cancer, 2005, 45, 74-75.	1.5	15
275	Plasma protein profiling: Unique and stable features of individuals. Proteomics, 2005, 5, 4012-4024.	2.2	67
276	Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells. Clinical Cancer Research, 2005, 11, 4561-4570.	7.0	30
277	Silencing Human NKG2D, DAP10, and DAP12 Reduces Cytotoxicity of Activated CD8+ T Cells and NK Cells. Journal of Immunology, 2005, 175, 7819-7828.	0.8	112
278	Pulmonary Cytolytic Thrombi after Allogeneic Hematopoietic Cell Transplantation: A Further Histologic Description. Biology of Blood and Marrow Transplantation, 2005, 11, 484-485.	2.0	19
279	Negative Impact of KIR-Ligand Mismatch on Transplant-Related Mortality (TRM) in Umbilical Cord Blood Transplant (UCBT) Recipients.. Blood, 2005, 106, 2041-2041.	1.4	2
280	The Unexpected and Differential Effect of Cyclosporin A on CD56Bright and CD56Dim NK Cell Expansion, Phenotype, Function and Development from Progenitor Cells.. Blood, 2005, 106, 1404-1404.	1.4	0
281	Maternal Hemoglobin Concentration during Pregnancy and Risk of Infant Leukemia.. Blood, 2005, 106, 4550-4550.	1.4	0
282	Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood, 2004, 103, 3065-3072.	1.4	345
283	Silencing Human NKG2D, DAP10 and DAP12 Reduces Cytotoxicity of in Vivo Activated CD8+ T and NK Cells.. Blood, 2004, 104, 446-446.	1.4	0
284	Cyclosporin Influences NK Cell Expansion, Activating and Inhibitory Receptor Expression and Cytokine Synthesis.. Blood, 2004, 104, 3868-3868.	1.4	0
285	The role of oxidant injury in the pathophysiology of human thalassemias. Redox Report, 2003, 8, 241-245.	4.5	45
286	Fetal microchimerism—what our children leave behind. Blood, 2003, 102, 3465-3466.	1.4	2
287	Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood, 2003, 101, 640-648.	1.4	302
288	Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. Journal of Clinical Immunology, 2002, 22, 131-136.	3.8	62

#	ARTICLE	IF	CITATIONS
289	High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: Atopy predicts idiopathic diffuse lung injury syndromes. Biology of Blood and Marrow Transplantation, 2001, 7, 49-57.	2.0	55
290	Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biology of Blood and Marrow Transplantation, 2001, 7, 532-542.	2.0	90
291	Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production. Blood, 2001, 97, 2923-2931.	1.4	218
292	Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunology Letters, 2001, 76, 169-173.	2.5	54
293	Resistance of ex vivo expanded CD3 + CD56 + T cells to Fas-mediated apoptosis. Cancer Immunology, Immunotherapy, 2000, 49, 335-345.	4.2	62
294	Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation. , 0, , 163-175.		0